The Chicago Entrepreneur

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.

Previous post Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
Next post Pfizer’s stock pops after earnings beat as company raises guidance and unveils cost cuts